|
20 Jul 2009 |
Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus
|
|
16 Jul 2009 |
Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting
|
|
16 Jul 2009 |
GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLD
|
|
15 Jul 2009 |
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
|
|
15 Jul 2009 |
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
|
|
15 Jul 2009 |
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 Enzyme
|
|
15 Jul 2009 |
XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
|
|
13 Jul 2009 |
NovImmune successfully completes NI-0801 Phase I clinical study
|
|
13 Jul 2009 |
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
|
|
10 Jul 2009 |
InNexus and Genhelix to Combine Antibody Development and Manufacturing Resources
|
|
09 Jul 2009 |
RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PIVOTAL CLL STUDY
|
|
09 Jul 2009 |
DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAX
|
|
09 Jul 2009 |
Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products
|
|
08 Jul 2009 |
ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)
|
|
08 Jul 2009 |
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
|
|
06 Jul 2009 |
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Zevalin
|
|
06 Jul 2009 |
MorphoSys Secures Full-Term of Strategic Alliance
|
|
03 Jul 2009 |
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
|
|
03 Jul 2009 |
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
|
|
02 Jul 2009 |
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
|
|
01 Jul 2009 |
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
|
|
30 Jun 2009 |
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
|
|
29 Jun 2009 |
ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R
|
|
26 Jun 2009 |
Cimzia®, the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis
|
|
26 Jun 2009 |
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
|
